Join to View Full Profile
300 Longwood AveBoston, MA 02115
Phone+1 617-355-8246
Fax+1 617-730-0641
Join Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Sudha Parasuraman, MD is a pediatric hematologist/oncologist in Boston, Massachusetts. She is currently licensed to practice medicine in Massachusetts, New Hampshire, and California.
Education & Training
University of TennesseeFellowship, Pediatric Hematology/Oncology, 1995 - 1998
University of Southern California/Los Angeles General Medical Center (USC/LA General)Residency, Pediatrics, 1994 - 1995
Children's Hospital of MichiganResidency, Pediatrics, 1992 - 1994
Kilpauk Medical CollegeClass of 1991
Certifications & Licensure
CA State Medical License 1994 - 2026
MA State Medical License 1998 - 2026
NH State Medical License 1998 - 2026
Publications & Presentations
PubMed
- 9 citationsMavorixafor, an Orally Bioavailable CXCR4 Antagonist, Increases Immune Cell Infiltration and Inflammatory Status of Tumor Microenvironment in Patients with Melanoma.Robert H I Andtbacka, Yan Wang, Robert H Pierce, Jean S Campbell, Melinda Yushak
Cancer Research Communications. 2022-08-01 - 27 citationsA phase 1b trial of the CXCR4 inhibitor mavorixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapy.Toni K. Choueiri, Michael B. Atkins, Tracy L. Rose, Robert S. Alter, Yawen Ju
Investigational New Drugs. 2021-01-28 - 116 citationsA phase I study of the CDK4/6 inhibitor ribociclib (LEE011) in pediatric patients with malignant rhabdoid tumors, neuroblastoma, and other solid tumorsBirgit Geoerger, Franck Bourdeaut, Steven G. DuBois, Matthias Fischer, James I. Geller
Clinical Cancer Research. 2017-05-15
Press Mentions
Ribon Therapeutics Announces Dosing of First Patient in Phase 1 Clinical Trial of RBN-2397, a First-in-Class PARP7 InhibitorSeptember 4th, 2019
Ribon Therapeutics Strengthens Management Team with Appointment of Sudha Parasuraman, M.D., as Chief Medical Officer and Edward Stewart as Chief Business OfficerAugust 6th, 2019- X4 Presents Data from Ongoing Phase 2 Study Demonstrating Promising Activity of x4p-001-RD in Patients with WHIM SyndromeJune 15th, 2018
- Join now to see all
